Application of physical parameter identification to finite-element models

The time domain parameter identification method described previously is applied to TRW's Large Space Structure Truss Experiment. Only control sensors and actuators are employed in the test procedure. The fit of the linear structural model to the test data is improved by more than an order of magnitude using a physically reasonable parameter set. The electro-magnetic control actuators are found to contribute significant damping due to a combination of eddy current and back electro-motive force (EMF) effects. Uncertainties in both estimated physical parameters and modal behavior variables are given

Application of physical parameter identification to finite element models

A time domain technique for matching response predictions of a structural dynamic model to test measurements is developed. Significance is attached to prior estimates of physical model parameters and to experimental data. The Bayesian estimation procedure allows confidence levels in predicted physical and modal parameters to be obtained. Structural optimization procedures are employed to minimize an error functional with physical model parameters describing the finite element model as design variables. The number of complete FEM analyses are reduced using approximation concepts, including the recently developed convoluted Taylor series approach. The error function is represented in closed form by converting free decay test data to a time series model using Prony' method. The technique is demonstrated on simulated response of a simple truss structure

The Challenge of Prognosis and Staging for Hepatocellular Carcinoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/140053/1/onco0023.pd

Two-Stage Passive Vibration Isolator

The design and testing of a structural system were implemented to hold the optics of the planned Space Interferometry Mission (SIM) at positions and orientations characterized by vibrational translation and rotation errors of no more than a few nanometers or a few milliarcseconds, respectively. Much of the effort was devoted to a test bed for verifying the predicted behavior of a vibration- isolation structural subsystem working together with an active control system for positioning and orienting the SIM optics. There was considerable emphasis on the vibration-isolation subsystem, which was passive and comprised two stages. The main sources of vibration were six reaction wheels in an assembly denoted the "backpack." The first vibration-isolation stage consisted of hexapod isolator mounts - one for each reaction wheel - characterized by a natural vibration frequency of 10 Hz. The second stage was a set of three beams, disposed between the backpack and the structure that held the SIM optics, that were flexured such that they transmitted only bending loads, with a natural vibrational frequency and damping of about 5 Hz and 4 percent, respectively. Preliminary test results were presented and characterized as demonstrating the effectiveness of the two-stage vibration-isolation design

Current Approaches to the Treatment of Early Hepatocellular Carcinoma

Peer Reviewedhttps://deepblue.lib.umich.edu/bitstream/2027.42/139902/1/onco0034.pd

Active Structural Elements within a General Vibration Control Framework

High-precision machines typically suffer from small but annoying vibrations. As the most appropriate solution to a particular vibration problem is not always obvious, it may be convenient to cast the problem in a more general framework. This framework may then be used for frequency response analysis, which, together with close examination of the disturbance sources, leads to a solution in general structural terms, like ‘vibration isolation’, ‘stiffness enhancement’ or ‘damping augmentation’. In case it is not possible or unpractical to control the vibration passively, a solution based on active structural elements may be considered

Boceprevir for untreated chronic HCV genotype 1 infection.

International audienceBACKGROUND: Peginterferon-ribavirin therapy is the current standard of care for chronic infection with hepatitis C virus (HCV). The rate of sustained virologic response has been below 50% in cases of HCV genotype 1 infection. Boceprevir, a potent oral HCV-protease inhibitor, has been evaluated as an additional treatment in phase 1 and phase 2 studies. METHODS: We conducted a double-blind study in which previously untreated adults with HCV genotype 1 infection were randomly assigned to one of three groups. In all three groups, peginterferon alfa-2b and ribavirin were administered for 4 weeks (the lead-in period). Subsequently, group 1 (the control group) received placebo plus peginterferon-ribavirin for 44 weeks; group 2 received boceprevir plus peginterferon-ribavirin for 24 weeks, and those with a detectable HCV RNA level between weeks 8 and 24 received placebo plus peginterferon-ribavirin for an additional 20 weeks; and group 3 received boceprevir plus peginterferon-ribavirin for 44 weeks. Nonblack patients and black patients were enrolled and analyzed separately. RESULTS: A total of 938 nonblack and 159 black patients were treated. In the nonblack cohort, a sustained virologic response was achieved in 125 of the 311 patients (40%) in group 1, in 211 of the 316 patients (67%) in group 2 (P<0.001), and in 213 of the 311 patients (68%) in group 3 (P<0.001). In the black cohort, a sustained virologic response was achieved in 12 of the 52 patients (23%) in group 1, in 22 of the 52 patients (42%) in group 2 (P=0.04), and in 29 of the 55 patients (53%) in group 3 (P=0.004). In group 2, a total of 44% of patients received peginterferon-ribavirin for 28 weeks. Anemia led to dose reductions in 13% of controls and 21% of boceprevir recipients, with discontinuations in 1% and 2%, respectively. CONCLUSIONS: The addition of boceprevir to standard therapy with peginterferon-ribavirin, as compared with standard therapy alone, significantly increased the rates of sustained virologic response in previously untreated adults with chronic HCV genotype 1 infection. The rates were similar with 24 weeks and 44 weeks of boceprevir

First interim analysis of the GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib) non‐interventional study

Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/92068/1/j.1742-1241.2012.02940.x.pd